pateclizumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
pateclizumab

GtoPdb Ligand ID: 9854

Synonyms: MLTA3698A | PRO283698 | RG7416

Compound class: Antibody

Comment: Pateclizumab is a humanized anti-lymphotoxin alpha (LTA) monoclonal antibody that is being investigated for anti-inflammatory potential. Peptide sequences for the heavy and light chains of pateclizumab are 100% matches to sequences 106 and 107 that are claimed in Genentech's patent US7923011B2 [1]. Sequences 106 and 107 identify pateclizumab as antibody 2C8.vX as defined in the patent.

References
1. Adams CW, Grogan JL, Gurney AL, McCutcheon K. (2011) Antibodies to lymphotoxin-alpha. Patent number: US7923011B2. Assignee: Genentech Inc. Priority date: 12/10/2006. Publication date: 12/04/2011.
2. Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC. (2012) Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Arthritis Res Ther, 14 (1): R6. [PMID:22225620]
3. Hirose T, Fukuma Y, Takeshita A, Nishida K. (2018) The role of lymphotoxin-α in rheumatoid arthritis. Inflamm Res, 67 (6): 495-501. [PMID:29541795]
4. Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC. (2014) Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Res Ther, 16 (5): 467. [PMID:25359150]

References

1. Adams CW, Grogan JL, Gurney AL, McCutcheon K. (2011)
Antibodies to lymphotoxin-alpha.
Patent number: US7923011B2. Assignee: Genentech Inc. Priority date: 12/10/2006. Publication date: 12/04/2011.

2. Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC. (2012)
Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.
Arthritis Res Ther, 14 (1): R6. [PMID:22225620]

3. Hirose T, Fukuma Y, Takeshita A, Nishida K. (2018)
The role of lymphotoxin-α in rheumatoid arthritis.
Inflamm Res, 67 (6): 495-501. [PMID:29541795]

4. Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC. (2014)
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
Arthritis Res Ther, 16 (5): 467. [PMID:25359150]